Usage Information

Jet-injected combinational adjuvants potentiate naked mRNA vaccines for protection against respiratory viral infections in mice
Nan Qiao, Junichi Ishikawa, Fumihiko Yasui, Kaori Sano, Kei Miyakawa, Akimasa Hayashi, Ahmad Faisal Amiry, Haonan Liu, Xueyang Zhu, Naoko Takeda-Miyata, Motohiro Kojima, Taku Sato, Renata Pasqualini, Wadih Arap, Kazunori Kataoka, Hideki Hasegawa, Michinori Kohara, Satoshi Uchida
Nan Qiao, Junichi Ishikawa, Fumihiko Yasui, Kaori Sano, Kei Miyakawa, Akimasa Hayashi, Ahmad Faisal Amiry, Haonan Liu, Xueyang Zhu, Naoko Takeda-Miyata, Motohiro Kojima, Taku Sato, Renata Pasqualini, Wadih Arap, Kazunori Kataoka, Hideki Hasegawa, Michinori Kohara, Satoshi Uchida
View: Text | PDF
Research In-Press Preview Immunology Infectious disease

Jet-injected combinational adjuvants potentiate naked mRNA vaccines for protection against respiratory viral infections in mice

Abstract

The use of lipid nanoparticles (LNPs) to enhance delivery and immunogenicity of mRNA vaccines raises safety concerns due to strong reactogenicity. Developing naked mRNA vaccines, which can be delivered through liquid jet-injection to the skin, may offer a safer alternative, but their immunogenicity has been limited. To address this challenge, we screened clinically relevant adjuvants to enhance the efficacy of N1-methyl-pseudouridine-modified naked mRNA jet-injection vaccines in mouse models. Although many adjuvants showed little or inhibitory effects on inducing humoral or cellular immunity—despite their known ability to potentiate conventional non-mRNA vaccine platforms—we identified a combination of aluminum phosphate and CpG oligonucleotide that substantially enhanced both humoral and cellular immune responses with increased IgG2a/IgG1 ratio. This adjuvanted naked mRNA vaccine induced IgG2a and cellular immunity at levels comparable to those achieved with LNPs but with lower local and systemic reactogenicity. Mechanistic investigations revealed key roles for type I interferon and interleukin-6 signaling during immunization. Notably, this vaccine formulation in mice virtually eliminated infection by both SARS-CoV-2 and influenza A virus (A/California/7/2009 H1N1) in plaque-forming assays. Collectively, the adjuvanted naked mRNA jet-injection vaccine represents an effective, and safe platform against infectious diseases, with potential for clinic-ready translational applications.

Authors

Nan Qiao, Junichi Ishikawa, Fumihiko Yasui, Kaori Sano, Kei Miyakawa, Akimasa Hayashi, Ahmad Faisal Amiry, Haonan Liu, Xueyang Zhu, Naoko Takeda-Miyata, Motohiro Kojima, Taku Sato, Renata Pasqualini, Wadih Arap, Kazunori Kataoka, Hideki Hasegawa, Michinori Kohara, Satoshi Uchida

×

Usage data is cumulative from October 2026 through October 2026.

Usage JCI PMC
Text version 647 0
PDF 153 0
Supplemental data 24 0
Citation downloads 47 0
Totals 871 0
Total Views 871

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement